Dimerix Limited (ASX: DXB) - Share Price

Current share price for DXB : $0.205 0.005 (2.38%)⁺

Dimerix Limited (DXB) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage biopharmaceutical company focused on improving the lives of patients with inflammatory diseases, including kidney disease. The company is developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for orphan respiratory / renal Disease. Both DMX-200 and DMX-700 were identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable and globally applicable technology platform that enables the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

DXB General Information ⁺

ASX Code	DXB
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	123
DXB Share Price	$0.205
Day High	$0.215
Day Low	$0.205
Last Close	$0.210
DXB Share Price Movement	$0.01 ( 2.38% )

Prices as at 16:40, 20 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Dimerix Limited (DXB) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Dimerix Limited (DXB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Dimerix Limited (DXB) price-sensitive announcements

DXB - DMX-200 First 100 Patients Complete Phase 3 Trial Treatment

Dimerix Limited announced that the first 100 patients in its pivotal ACTION3 Phase 3 trial

Dimerix Limited (DXB)
16 Oct 2026 | 8:52 AM

DXB - First Patient Reaches Four Years in DMX-200 Clinical Program

Dimerix Limited announced that the first patient has completed four years in the DMX-200 c

Dimerix Limited (DXB)
5 Oct 2026 | 8:56 AM

DXB - Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility

Dimerix Limited announced that it has completed an initial drawdown of approximately A$17

Dimerix Limited (DXB)
23 Sep 2026 | 8:36 AM

DXB - Dimerix DMX-652 Granted Mexican Composition of Matter Patent

Dimerix Limited announced that the Mexican Institute of Industrial Property granted a comp

Dimerix Limited (DXB)
14 Sep 2026 | 8:39 AM

Dimerix Limited (DXB) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$123	Dimerix Announces Board Chair Transition	19 Oct 2026 8:30AM	$0.220	$0.205	fallen by 6.82%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$123	DMX-200 First 100 Patients Complete Phase 3 Trial Treatment	16 Oct 2026 8:52AM	$0.210	$0.205	fallen by 2.38%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$123	Dimerix at Canaccord Drug & Device and Ignite Conferences	12 Oct 2026 8:32AM	$0.220	$0.205	fallen by 6.82%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$123	First Patient Reaches Four Years in DMX-200 Clinical Program	5 Oct 2026 8:56AM	$0.225	$0.205	fallen by 8.89%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$123	Notification regarding unquoted securities - DXB	28 Sep 2026 2:34PM	$0.228	$0.205	fallen by 9.89%
Dimerix Limited (DXB) ORDINARY FULLY PAID	Health Care	$123	Notification of 2026 Annual General Meeting Date	25 Sep 2026 2:42PM	$0.230	$0.205	fallen by 10.87%

DXB Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$29.81	-$5.00	110.60%	0.00%	0.0%
2025A	-$13.25	-$2.40	-37.40%	0.00%	0.0%
2024A	-$17.08	-$3.80	-11.10%	0.00%	0.0%

DXB Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
CSL Limited (CSL)	$92,234M	0.7309	-0.4410	0.0602	11.9072	21.3018	20.0926	2.21%	2.21%	2.28%
Dimerix Limited (DXB)	$132M	1.1059	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,590M	-0.4501	0.0000	0.0000	0.0000	0.0000	310.9375	0.00%	0.00%	0.00%
PYC Therapeutics Limited (PYC)	$1,880M	-0.3971	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,353M	-1.3893	0.0000	-0.5230	0.0000	185.7143	389.3564	0.00%	0.00%	0.00%

DXB Directors

Name	Position	Start Date
Dr Nina Webster	Chief Executive Officer, Managing Director	27 Aug 2018
Mr Mark P Diamond	Non-Executive Chairman, Non-Executive Director	1 Dec 2023
Mr Hugh Alsop	Non-Executive Director	1 May 2017
Dr Sonia Maria Poli	Non-Executive Director	3 Jul 2015
Mr Clinton Snow	Non-Executive Director	1 May 2023

Dimerix Limited (DXB) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
12 Dec 2025	SNOW, Clinton	Issued	Options	300,000	$0.321	$96,300.000
12 Dec 2025	ALSOP, Hugh	Issued	Options	300,000	$0.321	$96,300.000
12 Dec 2025	WEBSTER, Nina	Issued	Options	2,500,000	$0.437	$1,093,500.000

See all changes in directors' interest & trades for Dimerix Limited (DXB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

DXB Management

Name	Position
Michael (Mike) Tonroe	Chief Financial Officer,Company Secretary
Dr David Fuller	Chief Medical Officer
Dr Robert Shepherd	Chief Operating Officer

DXB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Dimerix Limited (DXB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
91,640,374 (15.26%)	Mr Peter Meurs

DXB Calendar of Events

Date	Event
26 August 2027	Report (Annual)
26 August 2027	Report (Prelim)
25 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us